

Patient ID	Gender /Age	Karyotype	FAB	ELN 2010 risk	% blasts in BM/ PB
TM10	m/70	91,XXYY,del(2)(q32q37),der(5)t(?;5)(?;p14)del(5)(q14q35),+13,+13 3, -17,-21,-21 [1] / 46,XY [8]	M1	adverse	78 / 82 (bone marrow)
019	m/66	46,XY [21]	M1	int-1	76 / 78
TM03	f/82	46,XX [20]	M2	int-1	n.a. / 72
TM11	f/68	46,XX [20]	M2	int-1	n.a. / 77
005	f/60	47,XX,t(8;21)(q22;q22),+mar[20]	M2	favorable	45 / 40 *
TM04	m/47	46,XY,del(11)(q14q25) [19] / 46,XY,t(3;15)(p11;q21),del(11)(q14q25) [2]	M4	int-2	37 / 31 *
010	f/47	46,XX,del(7)(q31q36),inv(16)(p13.1q22)[2] / 47,XX,del(7)(q31q36),+8,inv(16)(p13.1q22) [10] / 47,XX,del(7)(q31q36),inv(16)(p13.1q22),+22 [6] / 50,XX,+6,+8,+13,inv(16)(p13.1q22),+22 [2] / 46,XX [1]	M4	favorable	25 / 22 *
016	m/74	46,XY,del(20)(q11q13)[20]	M4	int-2	90 / 90
CD34_1	m				
CD34_2	m				
CD34_3	m				
CD34_5	f				
CD34_8	f				

* enrichment of peripheral blood blasts

Supplemental Table 1